Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Concordia Healthcare Corp. T.CXR.R



TSX:CXR.R - Post by User

Post by retiredcfon Jan 07, 2016 8:12am
148 Views
Post# 24435783

James Telfser

James TelfserSecond stock in the clip. As can be seen, it's also the largest holding in his fund. GLTA

https://www.bnn.ca/Video/player.aspx?vid=782568

Fund Profile

Aventine Canadian Equity Fund

Aventine Canadian Equity Fund was the top Canadian Equity Fund in 2015, according to Morningstar.

ACE Fund finished 2015 up 12.7% versus the TSX down -8.3% and the category down over 3%.

Performance as of: December 2015

Fund Index*

1 Month (DEC) 0.9% -3.1%

1 Year12.7% -8.3%

Since Inception (Mar 31, 2014) – Annualized10.9% -2.6%

* Index: S&P/TSX Composite Total Return Index

* Returns are net of fees and include reinvested dividends


Top 5 holdings and weightings:
 

Concordia Healthcare - 7.1%

goeasy - 6.0%

Clearwater Seafoods Inc. - 5.8%

New Flyer Industries - 4.5%

Winpak - 4.4%

 
CXR-T 2016-01-06 COMMENT James Telfser
 
This is one of the best opportunities in Canada. An extremely cheap undervalued stock that gets painted with the same brush as Valeant (VRX-T). They made an acquisition he liked, which is going to generate a lot of cash flow going forward. Debt is high at 5 to 6 times EBITDA, above the range that he would typically like. However, as a company that sells legacy pharmaceuticals and orphan drugs, high margin drugs that generate a lot of cash, they are going to pay off that debt quite quickly. As that happens, you are going to see the multiple expand.
 
Login to show your approval   Login to show your disapproval / Be the first to comment
Price:
$56.900
Subject:
CANADIAN
Bias:
BEARISH
Owned:
Yes
<< Previous
Bullboard Posts
Next >>